Agreements, Financial Results, Clinical Study Results, Debt Financing, and Drug Application Updates - Analyst Notes on Tesaro,

  Agreements, Financial Results, Clinical Study Results, Debt Financing, and
  Drug Application Updates - Analyst Notes on Tesaro, Chelsea Therapeutics,
                         Venaxis, Geron, and Unilife

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, March 19, 2014

NEW YORK, March 19, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Tesaro, Inc.
(NASDAQ: TSRO), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP),
Venaxis, Inc. (NASDAQ: APPY), Geron Corporation (NASDAQ: GERN), and Unilife
Corporation (NASDAQ: UNIS). Private wealth members receive these notes ahead
of publication. To reserve complementary membership, limited openings are
available at:


On March 13, 2014, Tesaro, Inc. (Tesaro), along with AnaptysBio, Inc.,
announced an exclusive, worldwide license agreement and immuno-oncology
antibody collaboration. According to the Company, under the terms of
agreement, Tesaro receives rights to monospecific antibody drug candidates
targeting TIM-3, LAG-3 and PD-1 and dual reactive antibody drug candidates
targeting PD-1/TIM-3 and PD-1/LAG-3. Commenting on the collaboration, Mary
Lynne Hedley, Ph.D., President of Tesaro, stated, "This agreement provides
TESARO with a basis from which to develop novel therapeutics, including
combination-based approaches, against a variety of tumor targets and may
uniquely position TESARO for collaborations with new partners. The first
clinical trial from this collaboration is projected to begin in mid-2015, and
we expect to advance an additional candidate into clinical trials every one to
two quarters thereafter." The full analyst notes on Tesaro, Inc. are available
to download free of charge at:


On March 11, 2014, Chelsea Therapeutics International Ltd. (Chelsea
Therapeutics) reported its Q4 2013 and full-year 2013 financial results. Q4
2013 net loss was $5.3 million or $0.07 per diluted share, compared to Q4 2012
net loss of $2.2 million or $0.03 per diluted share. Net loss for full year
2013 was $16.4 million or $0.24 per diluted share, compared to net loss for
full year 2012 of $31.7 million or $0.47 per diluted share. Joseph G. Oliveto,
President and CEO of the Company, stated, "DA approval of NORTHERA™
(droxidopa) this February for symptomatic neurogenic orthostatic hypotension
is Chelsea Therapeutics' most important milestone to date. NORTHERA is the
first new treatment option approved for this indication in nearly two decades,
representing a significant market opportunity. We continue to pursue a dual
path of actively assessing the Company's strategic alternatives and preparing
for the commercial launch of NORTHERA." The full analyst notes on Chelsea
Therapeutics International Ltd. are available to download free of charge at:


On March 13, 2014, Venaxis, Inc. (Venaxis) announced positive top-line results
from its pivotal U.S. study. According to Venaxis, the APPY1 Test performed
well, with sensitivity and negative predictive value results that exceeded
those from the previous pilot study. Additionally, the Company stated that it
believes the pivotal results are sufficient for potential FDA clearance and
expects to finalize its 510(k) submission and file with the FDA. Steve Lundy,
President and CEO of the Company stated, "The positive outcome from this study
is a significant achievement for Venaxis, and I want to commend our team and
our clinical partners on a very well-run study. Our goal is to be well
positioned for successful product launch upon potential FDA clearance of the
APPY1 Test." The full analyst notes on Venaxis, Inc. are available to download
free of charge at:


On March 12, 2014, Geron Corporation (Geron) announced that the Company has
received verbal notice from the U.S. Food and Drug Administration (FDA) that
its Investigational New Drug (IND) application for imetelstat has been placed
on full clinical hold. According to Geron, the clinical hold affects all
ongoing Company-sponsored clinical trials. Additionally, the Company stated
that it has not yet received written notice of its clinical hold from the FDA
but based on the verbal communication, the FDA indicated that the clinical
hold is due to the occurrence of persistent low-grade liver function test
abnormalities observed in the Phase 2 study of imetelstat in ET/PV patients
and the potential risk of chronic liver injury following long-term exposure to
imetelstat. Geron added that it plans to work diligently with the FDA to seek
the release of the clinical hold. The full analyst notes on Geron Corporation
are available to download free of charge at:


On March 13, 2014, Unilife Corporation (Unilife) announced that it has entered
into a $60 million debt financing agreement with an affiliate of OrbiMed.
According to the Company, $40 million was funded to Unilife at the closing of
the deal, and two additional tranches of $10 million each will be provided to
the Company in December 2014 and June 2015, provided the Company is in
compliance with the terms of the agreement. Additionally, Unilife stated that
it will make interest-only payments to OrbiMed currently calculated at a rate
of 10.25% per annum, with the principal to be repaid by March 12, 2020, within
the six-year term of the agreement. Unilife Chairman and CEO Mr. Alan
Shortall, stated, "This $60 million commitment provides us with the necessary
capital to drive business growth as we bring several large contracts with
existing customers through to commercial rollout." The full analyst notes on
Unilife Corporation are available to download free of charge at:

We provide our members with a simple and reliable way to leverage our economy
of scale. Most investors do not have time to track all publicly traded
companies, much less perform an in-depth review and analysis of the
complexities contained in each situation. That's where Analysts Review comes
in. We provide a single unified platform for investors' to hear about what
matters. Situation alerts, moving events, and upcoming opportunities.



  oThis is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
  oInformation in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
  oThis information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
  oIf you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at pubco [at]
  oForanyurgentconcernsorinquiries, please contact us at compliance
  oAre you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to research [at] for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Analysts Review. An
outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Analysts Review in this article or
report according to the Procedures outlined by Analysts Review. Analysts
Review is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.


Analysts Review makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to be construed
as personal financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold any
securities mentioned herein.


Analysts Review is not responsible for any error which may be occasioned at
the time of printing of this document or any error, mistake or shortcoming. No
liability is accepted by Analysts Review whatsoever for any direct, indirect
or consequential loss arising from the use of this document. Analysts Review
expressly disclaims any fiduciary responsibility or liability for any
consequences, financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1) guarantee the
accuracy, timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The included
information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA

SOURCE Analysts Review

Contact: CONTACT PERSON: Adam Redford, CONTACT PHONE: +852-8191-3972
Press spacebar to pause and continue. Press esc to stop.